Health News Archive - April 29, 2009
ARNHEM, The Netherlands, April 29 /PRNewswire-FirstCall/ -- ARCADIS (EURONEXT: ARCAD), the international consulting, design, planning, engineering, and management services company today said that together with Stein Projektmanagement it has been awarded a contract for project management and technical consulting services for the new Hochtaunus hospital in Bad Homburg.
- 10th Annual State of the Air Report Publishes Local Air Quality Grades Online - WASHINGTON, April 29 /PRNewswire-USNewswire/ -- The 10th annual American Lung Association State of the Air report released today finds that six out of ten Americans -- 186.1 million people -- live in areas where air pollution levels endanger lives.
FARGO, N.D., April 29 /PRNewswire-USNewswire/ -- As cleanup from this year's record floods continue in the Fargo-Moorhead region, a new report from the American Lung Association is providing the city some badly needed good news.
ANTONY, France, April 29 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the release of the first year outcome of its phase IIb/III clinical trial (VO 57.07) on a sublingual house dust mite desensitization tablet. "We are very pleased with the outcome of this study, which is the first large study to ever demonstrate the efficacy of house dust mites allergen in treating perennial allergic rhinitis.
SYDNEY, April 29 /PRNewswire/ -- Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer.
Record Quarterly Revenues: $33.7 million vs. $25.2 million - Increase of 34% Record Quarterly Diluted EPS: $0.17 vs. $0.10 - Increase of 70% Operating Margins Improve to 11.9% OWINGS MILLS, Md., April 29 /PRNewswire-FirstCall/ -- Medifast, Inc.
STOCKHOLM, Sweden, April 29 /PRNewswire/ -- - Results to be Presented at World Congress of Nephrology 2009 Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease.
Landmark Bill to Advance Education and Informed Consent Recommendations Established by the Institutes of Medicine SAN BRUNO, Calif., April 29 /PRNewswire/ -- Cord Blood Registry (CBR), the global leader in the collection and preservation of newborn stem cells from umbilical cord blood, announced its support of legislation introduced by Congresswoman Jackie Speier (D-CA) entitled the "Cord Blood Education and Awareness Act of 2009." If passed, this ground-breaking legislation will require the Secretary of Health and Human Services to develop and disseminate public education materials that will educate patients and physicians on the value of umbilical cord blood stem cells and set standards for patients to document the choice they've made about banking their newborn's cord blood stem cells.
Aims to Raise Money for Housing NYC's Homeless & Mentally Ill NEW YORK, April 29 /PRNewswire/ -- May marks National Mental Health Month and to shed light on it, philanthropic-minded New Yorkers will raise money for Weston United's housing and support services for the mentally ill and physically disabled.
First-Quarter 2009 Highlights: - GAAP diluted EPS increased 16.0 percent to $0.58 from $0.50 in first-quarter 2008 - Diluted EPS, excluding $0.05 in amortization of intangible assets from the 2003 spin-off, increased 14.5 percent to $0.63 from $0.55 in first-quarter 2008 - Total net revenues increased 14.4 percent to a record $14.8 billion - Specialty pharmacy revenues increased 21.0 percent to a record $2.3 billion - Generic dispensing rate increased 3.5 percentage points to a record 66.8 percent - Cash flow from operations increased 7-fold to a record of nearly $1.2 billion 2009 Guidance Reaffirmed: - Full-year 2009 GAAP diluted EPS expected in the range of $2.45 to $2.55, representing 15 to 20 percent growth over 2008 - Full-year 2009 diluted EPS, excluding amortization of intangible assets, expected in the range of $2.67 to $2.77, representing 15 to 19 percent growth over 2008 FRANKLIN LAKES, N.J., April 29 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc.